Related Experiment Videos
Pulmonary mycoses. New concepts and new therapy
1Department of Medicine, Louisiana State University Medical Center, Shreveport 71130-3932.
Postgraduate Medicine
|July 1, 1988
Summary
Pathogenic fungi cause respiratory infections like histoplasmosis and aspergillosis. Oral imidazoles such as fluconazole show promise for treating these pulmonary mycoses, especially with rising infection rates.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Pulmonology
Background:
- Pathogenic and opportunistic fungi frequently cause human respiratory infections, including histoplasmosis, blastomycosis, aspergillosis, and invasive candidiasis.
- Increased incidence and severity of mycotic infections are linked to aggressive immunosuppressive therapies and the spread of acquired immunodeficiency syndrome (AIDS).
- These trends impact the diagnosis and treatment strategies for pulmonary mycoses.
Purpose of the Study:
- To review current and emerging therapeutic agents for pulmonary mycoses.
- To highlight the potential of oral imidazole antifungals in managing these infections.
Main Methods:
- Literature review of available and investigational treatments for pulmonary fungal infections.
- Focus on the efficacy and clinical trial status of oral imidazole antifungals.
Main Results:
- Several therapeutic agents are available or in clinical trials for pulmonary mycoses.
- Oral imidazoles, specifically ketoconazole, itraconazole, and fluconazole, demonstrate significant potential.
Conclusions:
- Oral imidazoles represent a promising class of drugs for treating pulmonary mycoses.
- Continued research and clinical trials are essential for optimizing antifungal therapy in immunocompromised patients.